Survival and perioperative outcomes of octo- and nonagenarians with resectable esophageal carcinoma
Diseases of the Esophagus · 2023-11-30 · 36 (12)
DOI: 10.1093/dote/doad043 ↗At a glance
Journal article in Diseases of the Esophagus, published online on 2023-07-13. Written by Nabeel Ahmed and 10 co-authors. Institution: Division of Thoracic and Upper Gastrointestinal Surgery, McGill University Health Centre, Montreal General Hospital, Montreal, Quebec, Canada. Major MEDLINE topics: Esophageal Neoplasms, Adenocarcinoma. Cited 3 times so far (Crossref); 28 references.
Abstract (original language)
The outcomes of different treatment modalities for patients aged 80 and above with locally advanced and resectable esophageal carcinoma are not well described. The aim of this study was to explore survival and perioperative outcomes among this specific group of patients. A retrospective, cohort analysis was performed on a prospectively maintained esophageal cancer database from the McGill regional upper gastroinestinal cancer network. Between 2010 and 2020, all patients ≥80 years with cT2-4a, Nany, M0 esophageal carcinoma were identified and stratified according to the treatment modality: Neoadjuvant chemotherapy (nCT) or chemoradiotherapy (nCRT); definitive CRT (dCRT); upfront surgery; palliative CT/RT; or best supportive care (BSC). Of the 162 patients identified, 79 were included in this study. The median age was 83 years (80–97), most were cT3 (73%), cN- (56%), and had adenocarcinoma (62%). Treatment included: nCT/nCRT (16/79, 20%); surgery alone (19/79, 24%); dCRT (12/29, 15%); palliative RT/CT (27/79, 34%); and BSC (5/79, 6%). Neoadjuvant treatment was completed in 10/16 (63%). Of the 35/79 who underwent surgery, major complications occurred in 13/35 (37%) and 90-day mortality in 3/35 (9%). Overall survival (OS) for the cohort at 1- and 3-years was 58% and 19%. Among patients treated with nCT/nCRT, this was 94% and 46% respectively. Curative intent treatment (nCT/nCRT/upfront surgery/dCRT) had significantly increased 1- and 3- year OS compared with non-curative treatment (76%/31% vs. 34%/3.3%). Multimodal standard of care treatment is feasible and safe in select octo/nonagenarians, and may be associated with improved OS. Age alone should not bias against treatment with curative intent.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Division of Thoracic and Upper Gastrointestinal Surgery, McGill University Health Centre, Montreal General Hospital, Montreal, Quebec, Canada.
- Division of Medical Oncology, McGill University Health Centre, Montreal, Quebec, Canada.
- Department of Radiation Oncology, McGill University Health Centre, Montreal, Quebec, Canada.
ORCID profiles: Nabeel Ahmed
Cite
APA
Ahmed, N., Tankel, J., Asselah, J., Alcindor, T., Alfieri, J., David, M., Najmeh, S., Spicer, J., Cools-Lartigue, J., Mueller, C., & Ferri, L. (2023). Survival and perioperative outcomes of octo- and nonagenarians with resectable esophageal carcinoma. Diseases of the Esophagus, 36(12). https://doi.org/10.1093/dote/doad043
Vancouver
Ahmed N, Tankel J, Asselah J, Alcindor T, Alfieri J, David M, et al. Survival and perioperative outcomes of octo- and nonagenarians with resectable esophageal carcinoma. Diseases of the Esophagus. 2023;36(12). doi:10.1093/dote/doad043
BibTeX
@article{Ahmed2023,
author = {Ahmed, Nabeel and Tankel, James and Asselah, Jamil and Alcindor, Thierry and Alfieri, Joanne and David, Marc and Najmeh, Sara and Spicer, Jonathan and Cools-Lartigue, Jonathan and Mueller, Carmen and Ferri, Lorenzo},
title = {Survival and perioperative outcomes of octo- and nonagenarians with resectable esophageal carcinoma},
journal = {Diseases of the Esophagus},
year = {2023},
volume = {36},
number = {12},
doi = {10.1093/dote/doad043}
}
EUVIMED